Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

85.31USD
21 Jul 2014
Price Change (% chg)

$0.25 (+0.29%)
Prev Close
$85.06
Open
$84.81
Day's High
$85.56
Day's Low
$84.50
Volume
1,089,858
Avg. Vol
--
52-wk High
--
52-wk Low
--

CELG.OQ

Chart for CELG.OQ

About

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in... (more)

Overall

Beta: 1.08
Market Cap (Mil.): $67,877.88
Shares Outstanding (Mil.): 798.00
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 54.16 35.20 35.57
EPS (TTM): 1.57 -- --
ROI: 13.34 18.94 18.22
ROE: 26.79 19.72 19.10
Search Stocks

Celgene drug can drive HIV out of hiding -study

* Scientists say finding is significant step in AIDS fight

12:30am EDT

Celgene's spondylitis drug misses main goal in trial

- Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.

09 Jul 2014

UPDATE 1-Celgene's spondylitis drug misses main goal in trial

July 9 - Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.

09 Jul 2014

Celgene spondylitis drug misses main goal in late-stage study

July 9 - Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.

09 Jul 2014

Celgene profit down but tops expectations; keeps forecast

- Celgene Corp on Thursday reported a slightly higher-than-expected first-quarter profit on increased sales of its flagship multiple myeloma drug Revlimid and other oncology products.

24 Apr 2014

UPDATE 1-Celgene profit down but tops expectations; keeps forecast

April 24 - Celgene Corp on Thursday reported a slightly higher-than-expected first-quarter profit on increased sales of its flagship multiple myeloma drug Revlimid and other oncology products.

24 Apr 2014

Celgene first quarter profit falls on higher costs

- Celgene Corp on Thursday reported lower first quarter profit on higher research and development costs and increased expenses for launching new medicines, although the company maintained its full year forecasts as sales also increased.

24 Apr 2014

Celgene first quarter profit falls on higher costs

April 24 - Celgene Corp on Thursday reported lower first quarter profit on higher research and development costs and increased expenses for launching new medicines, although the company maintained its full year forecasts as sales also increased.

24 Apr 2014

Mylan sues Celgene for blocking Revlimid, Thalomid generics

- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

03 Apr 2014

Mylan sues Celgene for blocking Revlimid, Thalomid generics

April 3 - Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.

03 Apr 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,673 +3.00
Eisai Co., Ltd (4523.T) ¥4,230 +13.50
Johnson & Johnson (JNJ.N) $101.27 -0.53
Pfizer Inc. (PFE.N) $30.35 -0.38
Novartis AG (NOVN.VX) CHF79.65 +0.15
Merck & Co., Inc. (MRK.N) $58.00 -0.34
Roche Holding Ltd. (ROG.VX) CHF263.30 +1.00
Abbott Laboratories (ABT.N) $42.96 +0.23
Sanofi SA (SASY.PA) €75.81 -0.26
AstraZeneca plc (AZN.L) 4,390.00p +50.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks